Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Equity (2016 - 2025)

Historic Return on Equity for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to 0.33%.

  • Spyre Therapeutics' Return on Equity rose 2900.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year increase of 2900.0%. This contributed to the annual value of 0.59% for FY2024, which is 23000.0% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Return on Equity is 0.33%, which was up 2900.0% from 0.44% recorded in Q2 2025.
  • Spyre Therapeutics' Return on Equity's 5-year high stood at 11.04% during Q4 2023, with a 5-year trough of 2.17% in Q1 2024.
  • For the 5-year period, Spyre Therapeutics' Return on Equity averaged around 0.07%, with its median value being 0.61% (2024).
  • Its Return on Equity has fluctuated over the past 5 years, first surged by 124600bps in 2023, then tumbled by -115300bps in 2024.
  • Spyre Therapeutics' Return on Equity (Quarter) stood at 0.71% in 2021, then tumbled by -101bps to 1.42% in 2022, then surged by 876bps to 11.04% in 2023, then plummeted by -104bps to 0.49% in 2024, then surged by 34bps to 0.33% in 2025.
  • Its Return on Equity stands at 0.33% for Q3 2025, versus 0.44% for Q2 2025 and 0.42% for Q1 2025.